Messaging Therapy for Depression and Anxiety: A Longitudinal Effectiveness Study

Anxiety Disorders Clinical Trial

Official title:

Asynchronous Messaging Therapy for Depression and Anxiety: A Longitudinal Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03699488
• Other study ID #: 1001
• Status: Completed
• Start date: January 1, 2016
• Est. completion date: February 1, 2018

Study information

• Verified date: February 2019
• Source: Talkspace
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Therapies delivered via technology have been developed to improve accessibility, however, there is limited research regarding messaging therapy in particular, and none that we know of utilizing a longitudinal effectiveness design. The aim of this study was to investigate the overall effectiveness of messaging therapy, identify any contributors to its effectiveness, and to evaluate a dosage effect for this type of treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12980
• Est. completion date: February 1, 2018
• Est. primary completion date: February 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Diagnosed Depression and/or Anxiety Disorder

Exclusion Criteria:

• Any psychosis related symptoms or disorders

Related Conditions & MeSH terms

• Anxiety Disorders
• Depression
• Depressive Symptoms

Intervention

Behavioral:
• psychotherapy via asynchronous message
Behavioral psychotherapy delivered by asynchronous message using the Talkspace application

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Talkspace	Columbia University, New York University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Depressive symptoms on the Patient Health Questionnaire - 9	Patient Health Questionnaire - 9 (PHQ-9) is a measure of depression symptoms. It has 9 items, with a minimum of 0 and a maximum of 27, with higher scores indicating more symptoms and distress. Decreasing scores indicate better outcome. All items are summed to give the summary score.	Up to 52 weeks
Primary	Change from Baseline in Anxiety symptoms on the Generalized Anxiety Disorder - 7	Generalized Anxiety Disorder - 7 (GAD-7) is a measure of anxiety symptoms. It has 7 items, with a minimum of 0 and a maximum of 21, with higher scores indicating more symptoms and distress. Decreasing scores indicate better outcome. All items are summed to give the summary score.	Up to 52 weeks
Secondary	Mean number of words sent from patient to therapist	Word counts of the words contained within messages sent	Up to 52 weeks
Secondary	Mean number of words sent from therapist to patient	Word counts of the words contained within messages sent	Up to 52 weeks